Net Asset Value • Mar 26, 2018
Net Asset Value
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 8420I
Hutchison China Meditech Limited
26 March 2018
London: Monday, March 26, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.chi-med.com).
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
| Investor Enquiries | ||
| Mark Lee, Senior Vice President, Corporate Finance & Development |
+852 2121 8200 | |
| U.K. & International Media Enquiries | ||
| Anthony Carlisle, Citigate Dewe Rogerson | +44 7973 611 888 (Mobile) | [email protected] |
| U.S. Based Media Enquiries | ||
| Brad Miles, BMC Communications | +1 (917) 570 7340 (Mobile) | [email protected] |
| Susan Duffy, BMC Communications | +1 (917) 499 8887 (Mobile) | [email protected] |
| Investor Relations | ||
| Matt Beck, The Trout Group | +1 (917) 415 1750 (Mobile) | [email protected] |
| David Dible, Citigate Dewe Rogerson | +44 7967 566 919 (Mobile) | [email protected] |
| Panmure Gordon (UK) Limited | ||
| Richard Gray / Andrew Potts | +44 (20) 7886 2500 |
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSPGUQAWUPRPUA
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.